Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571NIMMANAPALLI, Ramadevi; BHALLA, Kapil.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8584-8590, issn 0950-9232, 7 p.Article

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571NIMMANAPALLI, Ramadevi; BHALLA, Kapil.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8584-8590, issn 0950-9232, 7 p., NS7Article

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen : high efficacy of drug combinationsBRADEEN, Heather A; EIDE, Christopher A; O'HARE, Thomas et al.Blood. 2006, Vol 108, Num 7, pp 2332-2338, issn 0006-4971, 7 p.Article

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human t-cell responsesPINILLA-LBARZ, Javier; KORONTSVIT, Tatyana; ZAKHALEVA, Victoriya et al.Haematologica (Roma). 2005, Vol 90, Num 10, pp 1324-1332, issn 0390-6078, 9 p.Article

Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristicsBAIJUN FANG; CHUNMEI ZHENG; LIANMING LIAO et al.Blood. 2005, Vol 105, Num 7, pp 2733-2740, issn 0006-4971, 8 p.Article

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaDEININGER, Michael; BUCHDUNGER, Elisabeth; DRUKER, Brian J et al.Blood. 2005, Vol 105, Num 7, pp 2640-2653, issn 0006-4971, 14 p.Article

The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cellsAICHBERGER, Karl J; MAYERHOFER, Matthias; PICKL, Winfried F et al.Blood. 2006, Vol 108, Num 10, pp 3538-3547, issn 0006-4971, 10 p.Article

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationNOTARI, Mario; NEVIANI, Paolo; PERROTTI, Danilo et al.Blood. 2006, Vol 107, Num 6, pp 2507-2516, issn 0006-4971, 10 p.Article

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLWHITE, Deborah; SAUNDERS, Verity; LYONS, A. Bruce et al.Blood. 2005, Vol 106, Num 7, pp 2520-2526, issn 0006-4971, 7 p.Article

STAT5 signaling is required for the efficient induction and maintenance of CML in miceDAN YE; WOLFF, Nicholas; LI LI et al.Blood. 2006, Vol 107, Num 12, pp 4917-4925, issn 0006-4971, 9 p.Article

SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-AblJING CHEN; YU, Wen-Mei; DAINO, Hanako et al.Blood. 2007, Vol 109, Num 2, pp 778-785, issn 0006-4971, 8 p.Article

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia : an attempt to define patients who may not require further therapy. CommentaryMAZIARZ, Richard T; KAEDA, Jaspal; GOLDMAN, John M et al.Blood. 2006, Vol 107, Num 10, issn 0006-4971, 3820,4171-4176 [7 p.]Article

BCR/ABL promotes dendritic cell-mediated natural killer cell activationTERME, Magali; BORG, Christophe; ZITVOGEL, Laurence et al.Cancer research (Baltimore). 2005, Vol 65, Num 14, pp 6409-6417, issn 0008-5472, 9 p.Article

An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylateLEGUAY, T; DESPLAT, V; LAGARDE, V et al.Leukemia. 2005, Vol 19, Num 9, pp 1671-1673, issn 0887-6924, 3 p.Article

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitorsVON BUBNOFF, Nikolas; VEACH, Darren R; MILLER, W. Todd et al.Cancer research (Baltimore). 2003, Vol 63, Num 19, pp 6395-6404, issn 0008-5472, 10 p.Article

The hepoxilin analog PBT-3 induces apoptosis in BCR-ABL-positive K562 Leukemia cellsNA QIAO; LAM, Janice; REYNAUD, Denis et al.Anticancer research. 2003, Vol 23, Num 5A, pp 3617-3622, issn 0250-7005, 6 p.Article

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph⁺ leukemia activity of imatinib mesylateKURODA, Junya; KIMURA, Shinya; MAEKAWA, Taira et al.Blood. 2003, Vol 102, Num 6, pp 2229-2235, issn 0006-4971, 7 p.Article

High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutationsVIVANTE, A; AMARIGLIO, N; KOREN-MICHOWITZ, M et al.Leukemia. 2007, Vol 21, Num 6, pp 1318-1321, issn 0887-6924, 4 p.Article

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaSCHIFFER, Charles A.The New England journal of medicine. 2007, Vol 357, Num 3, pp 258-265, issn 0028-4793, 8 p.Article

The second generation of BCR-ABL tyrosine kinase inhibitors : PIH: New era of leukemia therapyTAUCHI, Tetsuzo; OHYASHIKI, Kazuma.International journal of hematology. 2006, Vol 83, Num 4, pp 294-300, issn 0925-5710, 7 p.Article

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivityHAWKINS, Lindsay M; JAYANTHAN, Aarthi A; NARENDRAN, Aru et al.Pediatric research. 2005, Vol 57, Num 3, pp 430-437, issn 0031-3998, 8 p.Article

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsO'HARE, Thomas; WALTERS, Denise K; DRUKER, Brian J et al.Cancer research (Baltimore). 2005, Vol 65, Num 11, pp 4500-4505, issn 0008-5472, 6 p.Article

N-acetyl-cysteine enhances growth in BCR-ABL- transformed cellsQIGUO ZHANG; TSUKAHARA, Fujiko; MARU, Yoshiro et al.Cancer science. 2005, Vol 96, Num 4, pp 240-244, issn 1347-9032, 5 p.Article

e6a2 BCR/ABL fusion with cryptic der(9)t(9;22) deletions in a patient with chronic mmyeloid leukemiaROTI, Giovanni; LA STARZA, Roberta; GORELLO, Paolo et al.Haematologica (Roma). 2005, Vol 90, Num 8, pp 1139-1141, issn 0390-6078, 3 p.Article

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaDONATO, Nicholas J; WU, Ji Y; TALPAZ, Moshe et al.Cancer research (Baltimore). 2004, Vol 64, Num 2, pp 672-677, issn 0008-5472, 6 p.Article